Global Ioversol

Ioversol Comprehensive Study by Type (Ioversol 34% Injectable Solution (Optiray 160), Ioversol 51% Injectable Solution (Optiray 240), Ioversol 64% Injectable Solution (Optiray 300), Ioversol 68% Injectable Solution (Optiray 320), Ioversol 74% Injectable Solution (Optiray 350)), Application (X-Ray, CT Scan, Brain Disorders, Blood Vessel Disorders, Heart Disorders, Others) Players and Region - Europe Market Outlook to 2030

Ioversol Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Ioversol is an organic compound used to allow various human body parts such as organs, blood vessels, and others to be seen more accurately thereby helping physicians in diagnosing various chronic diseases and bone injuries. It is available in different concentrations as well ranging from 240 to 350 mg of iodine per millimeter. Growing advancement in medical imaging technologies, and introduction of mobile medical imaging techniques provides huge boost to ioversol chemical.

Highlights from Ioversol Market Study
AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The key Vendors profiled in the report are Liebel-Flarsheim Company (United States), Guerbet (France), Jiangsu Hengrui Medicine (China), Mallinckrodt Pharmaceuticals (United Kingdom) and China Resources Pharmaceutical (Shanghai) Co, (China). Additionally, other players that are part of this comprehensive study are Novalek Pharmaceuticals Pvt. Ltd (India), Stellence Pharmscience Pvt. Ltd (India) and A.S. Joshi & Company (India).

Geographic Breakdown and Segment Analysis
The Europe Ioversol market presents a comprehensive analysis of the Ioversol market by product type (Ioversol 34% Injectable Solution (Optiray 160), Ioversol 51% Injectable Solution (Optiray 240), Ioversol 64% Injectable Solution (Optiray 300), Ioversol 68% Injectable Solution (Optiray 320) and Ioversol 74% Injectable Solution (Optiray 350)), by end-user/application (X-Ray, CT Scan, Brain Disorders, Blood Vessel Disorders, Heart Disorders and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Europe Ioversol industry. Investors and Vendors can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Ioversol market

Analyst at AMA have segmented the market study of Europe Ioversol market by Type, Application and Region.

Influencing Trend:
Need for Proper Prescription of Doctor Before Use of Ioversol

Market Growth Drivers:
Growing Number of Chronic Diseases and Bone Disorders and Increasing Geriatric Population Leading to Rise in Prevalence of Diseases

Challenges:
Precautions Required Before Ioversol Injection and Stringent Regulatory Frameworks Related to Ioversol Chemical

Restraints:
Ill-effect Associated with Over Consumption of Ioversol and Lack of Research About Use of Ioversol Limits Its Application

Opportunities:
Technological Advancement in Medical Imaging Techniques and Increasing Healthcare Spending in Emerging Countries

Market Developments Activities:
In Decemer 2020 Guerbet (GBT), a global leader in medical imaging, announced that it received US Food and Drug Administration approval for the commercial sale of the Optiray® Imaging Bulk Package (IBP) in the United States, as well as FDA clearance of the LF IBP Transfer Set.
In July , 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and sodium ioxaglate) and Optimark (gadoversetamide)

Regulatory Insights:
Food and Drug Administration (FDA) regulates the use of Ioversol, dosages as per age, and usage for specific populations. The body also mandates manufacturers to apply RFID-Tagged syringe directions for use.

Global Ioversol is a fragmented market due to the presence of various players. The players are focusing on investing more in Launching Products. These will enhance their market presence. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.

Key Target Audience
Ioversol Manufacturers, Raw Materials Suppliers/Distributors, End-users Industries, Market Research and Consulting Firms, Potential Investors and Others

Report Objectives / Segmentation Covered

By Type
  • Ioversol 34% Injectable Solution (Optiray 160)
  • Ioversol 51% Injectable Solution (Optiray 240)
  • Ioversol 64% Injectable Solution (Optiray 300)
  • Ioversol 68% Injectable Solution (Optiray 320)
  • Ioversol 74% Injectable Solution (Optiray 350)
By Application
  • X-Ray
  • CT Scan
  • Brain Disorders
  • Blood Vessel Disorders
  • Heart Disorders
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Number of Chronic Diseases and Bone Disorders
      • 3.2.2. Increasing Geriatric Population Leading to Rise in Prevalence of Diseases
    • 3.3. Market Challenges
      • 3.3.1. Precautions Required Before Ioversol Injection
      • 3.3.2. Stringent Regulatory Frameworks Related to Ioversol Chemical
    • 3.4. Market Trends
      • 3.4.1. Need for Proper Prescription of Doctor Before Use of Ioversol
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Europe Ioversol, by Type, Application and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Europe Ioversol (Value)
      • 5.2.1. Europe Ioversol by: Type (Value)
        • 5.2.1.1. Ioversol 34% Injectable Solution (Optiray 160)
        • 5.2.1.2. Ioversol 51% Injectable Solution (Optiray 240)
        • 5.2.1.3. Ioversol 64% Injectable Solution (Optiray 300)
        • 5.2.1.4. Ioversol 68% Injectable Solution (Optiray 320)
        • 5.2.1.5. Ioversol 74% Injectable Solution (Optiray 350)
      • 5.2.2. Europe Ioversol by: Application (Value)
        • 5.2.2.1. X-Ray
        • 5.2.2.2. CT Scan
        • 5.2.2.3. Brain Disorders
        • 5.2.2.4. Blood Vessel Disorders
        • 5.2.2.5. Heart Disorders
        • 5.2.2.6. Others
      • 5.2.3. Europe Ioversol Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Europe Ioversol (Volume)
      • 5.3.1. Europe Ioversol by: Type (Volume)
        • 5.3.1.1. Ioversol 34% Injectable Solution (Optiray 160)
        • 5.3.1.2. Ioversol 51% Injectable Solution (Optiray 240)
        • 5.3.1.3. Ioversol 64% Injectable Solution (Optiray 300)
        • 5.3.1.4. Ioversol 68% Injectable Solution (Optiray 320)
        • 5.3.1.5. Ioversol 74% Injectable Solution (Optiray 350)
      • 5.3.2. Europe Ioversol by: Application (Volume)
        • 5.3.2.1. X-Ray
        • 5.3.2.2. CT Scan
        • 5.3.2.3. Brain Disorders
        • 5.3.2.4. Blood Vessel Disorders
        • 5.3.2.5. Heart Disorders
        • 5.3.2.6. Others
      • 5.3.3. Europe Ioversol Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Australia
          • 5.3.3.2.6. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Europe Ioversol (Price)
      • 5.4.1. Europe Ioversol by: Type (Price)
  • 6. Ioversol: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Liebel-Flarsheim Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Guerbet (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Jiangsu Hengrui Medicine (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mallinckrodt Pharmaceuticals (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. China Resources Pharmaceutical (Shanghai) Co, (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Europe Ioversol Sale, by Type, Application and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Europe Ioversol (Value)
      • 7.2.1. Europe Ioversol by: Type (Value)
        • 7.2.1.1. Ioversol 34% Injectable Solution (Optiray 160)
        • 7.2.1.2. Ioversol 51% Injectable Solution (Optiray 240)
        • 7.2.1.3. Ioversol 64% Injectable Solution (Optiray 300)
        • 7.2.1.4. Ioversol 68% Injectable Solution (Optiray 320)
        • 7.2.1.5. Ioversol 74% Injectable Solution (Optiray 350)
      • 7.2.2. Europe Ioversol by: Application (Value)
        • 7.2.2.1. X-Ray
        • 7.2.2.2. CT Scan
        • 7.2.2.3. Brain Disorders
        • 7.2.2.4. Blood Vessel Disorders
        • 7.2.2.5. Heart Disorders
        • 7.2.2.6. Others
      • 7.2.3. Europe Ioversol Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Europe Ioversol (Volume)
      • 7.3.1. Europe Ioversol by: Type (Volume)
        • 7.3.1.1. Ioversol 34% Injectable Solution (Optiray 160)
        • 7.3.1.2. Ioversol 51% Injectable Solution (Optiray 240)
        • 7.3.1.3. Ioversol 64% Injectable Solution (Optiray 300)
        • 7.3.1.4. Ioversol 68% Injectable Solution (Optiray 320)
        • 7.3.1.5. Ioversol 74% Injectable Solution (Optiray 350)
      • 7.3.2. Europe Ioversol by: Application (Volume)
        • 7.3.2.1. X-Ray
        • 7.3.2.2. CT Scan
        • 7.3.2.3. Brain Disorders
        • 7.3.2.4. Blood Vessel Disorders
        • 7.3.2.5. Heart Disorders
        • 7.3.2.6. Others
      • 7.3.3. Europe Ioversol Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Australia
          • 7.3.3.2.6. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Europe Ioversol (Price)
      • 7.4.1. Europe Ioversol by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ioversol: by Type(USD Million)
  • Table 2. Ioversol Ioversol 34% Injectable Solution (Optiray 160) , by Region USD Million (2018-2023)
  • Table 3. Ioversol Ioversol 51% Injectable Solution (Optiray 240) , by Region USD Million (2018-2023)
  • Table 4. Ioversol Ioversol 64% Injectable Solution (Optiray 300) , by Region USD Million (2018-2023)
  • Table 5. Ioversol Ioversol 68% Injectable Solution (Optiray 320) , by Region USD Million (2018-2023)
  • Table 6. Ioversol Ioversol 74% Injectable Solution (Optiray 350) , by Region USD Million (2018-2023)
  • Table 7. Ioversol: by Application(USD Million)
  • Table 8. Ioversol X-Ray , by Region USD Million (2018-2023)
  • Table 9. Ioversol CT Scan , by Region USD Million (2018-2023)
  • Table 10. Ioversol Brain Disorders , by Region USD Million (2018-2023)
  • Table 11. Ioversol Blood Vessel Disorders , by Region USD Million (2018-2023)
  • Table 12. Ioversol Heart Disorders , by Region USD Million (2018-2023)
  • Table 13. Ioversol Others , by Region USD Million (2018-2023)
  • Table 14. South America Ioversol, by Country USD Million (2018-2023)
  • Table 15. South America Ioversol, by Type USD Million (2018-2023)
  • Table 16. South America Ioversol, by Application USD Million (2018-2023)
  • Table 17. Brazil Ioversol, by Type USD Million (2018-2023)
  • Table 18. Brazil Ioversol, by Application USD Million (2018-2023)
  • Table 19. Argentina Ioversol, by Type USD Million (2018-2023)
  • Table 20. Argentina Ioversol, by Application USD Million (2018-2023)
  • Table 21. Rest of South America Ioversol, by Type USD Million (2018-2023)
  • Table 22. Rest of South America Ioversol, by Application USD Million (2018-2023)
  • Table 23. Asia Pacific Ioversol, by Country USD Million (2018-2023)
  • Table 24. Asia Pacific Ioversol, by Type USD Million (2018-2023)
  • Table 25. Asia Pacific Ioversol, by Application USD Million (2018-2023)
  • Table 26. China Ioversol, by Type USD Million (2018-2023)
  • Table 27. China Ioversol, by Application USD Million (2018-2023)
  • Table 28. Japan Ioversol, by Type USD Million (2018-2023)
  • Table 29. Japan Ioversol, by Application USD Million (2018-2023)
  • Table 30. India Ioversol, by Type USD Million (2018-2023)
  • Table 31. India Ioversol, by Application USD Million (2018-2023)
  • Table 32. South Korea Ioversol, by Type USD Million (2018-2023)
  • Table 33. South Korea Ioversol, by Application USD Million (2018-2023)
  • Table 34. Australia Ioversol, by Type USD Million (2018-2023)
  • Table 35. Australia Ioversol, by Application USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Ioversol, by Type USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Ioversol, by Application USD Million (2018-2023)
  • Table 38. Europe Ioversol, by Country USD Million (2018-2023)
  • Table 39. Europe Ioversol, by Type USD Million (2018-2023)
  • Table 40. Europe Ioversol, by Application USD Million (2018-2023)
  • Table 41. Germany Ioversol, by Type USD Million (2018-2023)
  • Table 42. Germany Ioversol, by Application USD Million (2018-2023)
  • Table 43. France Ioversol, by Type USD Million (2018-2023)
  • Table 44. France Ioversol, by Application USD Million (2018-2023)
  • Table 45. Italy Ioversol, by Type USD Million (2018-2023)
  • Table 46. Italy Ioversol, by Application USD Million (2018-2023)
  • Table 47. United Kingdom Ioversol, by Type USD Million (2018-2023)
  • Table 48. United Kingdom Ioversol, by Application USD Million (2018-2023)
  • Table 49. Netherlands Ioversol, by Type USD Million (2018-2023)
  • Table 50. Netherlands Ioversol, by Application USD Million (2018-2023)
  • Table 51. Rest of Europe Ioversol, by Type USD Million (2018-2023)
  • Table 52. Rest of Europe Ioversol, by Application USD Million (2018-2023)
  • Table 53. MEA Ioversol, by Country USD Million (2018-2023)
  • Table 54. MEA Ioversol, by Type USD Million (2018-2023)
  • Table 55. MEA Ioversol, by Application USD Million (2018-2023)
  • Table 56. Middle East Ioversol, by Type USD Million (2018-2023)
  • Table 57. Middle East Ioversol, by Application USD Million (2018-2023)
  • Table 58. Africa Ioversol, by Type USD Million (2018-2023)
  • Table 59. Africa Ioversol, by Application USD Million (2018-2023)
  • Table 60. North America Ioversol, by Country USD Million (2018-2023)
  • Table 61. North America Ioversol, by Type USD Million (2018-2023)
  • Table 62. North America Ioversol, by Application USD Million (2018-2023)
  • Table 63. United States Ioversol, by Type USD Million (2018-2023)
  • Table 64. United States Ioversol, by Application USD Million (2018-2023)
  • Table 65. Canada Ioversol, by Type USD Million (2018-2023)
  • Table 66. Canada Ioversol, by Application USD Million (2018-2023)
  • Table 67. Mexico Ioversol, by Type USD Million (2018-2023)
  • Table 68. Mexico Ioversol, by Application USD Million (2018-2023)
  • Table 69. Ioversol Sales: by Type(K Units)
  • Table 70. Ioversol Sales Ioversol 34% Injectable Solution (Optiray 160) , by Region K Units (2018-2023)
  • Table 71. Ioversol Sales Ioversol 51% Injectable Solution (Optiray 240) , by Region K Units (2018-2023)
  • Table 72. Ioversol Sales Ioversol 64% Injectable Solution (Optiray 300) , by Region K Units (2018-2023)
  • Table 73. Ioversol Sales Ioversol 68% Injectable Solution (Optiray 320) , by Region K Units (2018-2023)
  • Table 74. Ioversol Sales Ioversol 74% Injectable Solution (Optiray 350) , by Region K Units (2018-2023)
  • Table 75. Ioversol Sales: by Application(K Units)
  • Table 76. Ioversol Sales X-Ray , by Region K Units (2018-2023)
  • Table 77. Ioversol Sales CT Scan , by Region K Units (2018-2023)
  • Table 78. Ioversol Sales Brain Disorders , by Region K Units (2018-2023)
  • Table 79. Ioversol Sales Blood Vessel Disorders , by Region K Units (2018-2023)
  • Table 80. Ioversol Sales Heart Disorders , by Region K Units (2018-2023)
  • Table 81. Ioversol Sales Others , by Region K Units (2018-2023)
  • Table 82. South America Ioversol Sales, by Country K Units (2018-2023)
  • Table 83. South America Ioversol Sales, by Type K Units (2018-2023)
  • Table 84. South America Ioversol Sales, by Application K Units (2018-2023)
  • Table 85. Brazil Ioversol Sales, by Type K Units (2018-2023)
  • Table 86. Brazil Ioversol Sales, by Application K Units (2018-2023)
  • Table 87. Argentina Ioversol Sales, by Type K Units (2018-2023)
  • Table 88. Argentina Ioversol Sales, by Application K Units (2018-2023)
  • Table 89. Rest of South America Ioversol Sales, by Type K Units (2018-2023)
  • Table 90. Rest of South America Ioversol Sales, by Application K Units (2018-2023)
  • Table 91. Asia Pacific Ioversol Sales, by Country K Units (2018-2023)
  • Table 92. Asia Pacific Ioversol Sales, by Type K Units (2018-2023)
  • Table 93. Asia Pacific Ioversol Sales, by Application K Units (2018-2023)
  • Table 94. China Ioversol Sales, by Type K Units (2018-2023)
  • Table 95. China Ioversol Sales, by Application K Units (2018-2023)
  • Table 96. Japan Ioversol Sales, by Type K Units (2018-2023)
  • Table 97. Japan Ioversol Sales, by Application K Units (2018-2023)
  • Table 98. India Ioversol Sales, by Type K Units (2018-2023)
  • Table 99. India Ioversol Sales, by Application K Units (2018-2023)
  • Table 100. South Korea Ioversol Sales, by Type K Units (2018-2023)
  • Table 101. South Korea Ioversol Sales, by Application K Units (2018-2023)
  • Table 102. Australia Ioversol Sales, by Type K Units (2018-2023)
  • Table 103. Australia Ioversol Sales, by Application K Units (2018-2023)
  • Table 104. Rest of Asia-Pacific Ioversol Sales, by Type K Units (2018-2023)
  • Table 105. Rest of Asia-Pacific Ioversol Sales, by Application K Units (2018-2023)
  • Table 106. Europe Ioversol Sales, by Country K Units (2018-2023)
  • Table 107. Europe Ioversol Sales, by Type K Units (2018-2023)
  • Table 108. Europe Ioversol Sales, by Application K Units (2018-2023)
  • Table 109. Germany Ioversol Sales, by Type K Units (2018-2023)
  • Table 110. Germany Ioversol Sales, by Application K Units (2018-2023)
  • Table 111. France Ioversol Sales, by Type K Units (2018-2023)
  • Table 112. France Ioversol Sales, by Application K Units (2018-2023)
  • Table 113. Italy Ioversol Sales, by Type K Units (2018-2023)
  • Table 114. Italy Ioversol Sales, by Application K Units (2018-2023)
  • Table 115. United Kingdom Ioversol Sales, by Type K Units (2018-2023)
  • Table 116. United Kingdom Ioversol Sales, by Application K Units (2018-2023)
  • Table 117. Netherlands Ioversol Sales, by Type K Units (2018-2023)
  • Table 118. Netherlands Ioversol Sales, by Application K Units (2018-2023)
  • Table 119. Rest of Europe Ioversol Sales, by Type K Units (2018-2023)
  • Table 120. Rest of Europe Ioversol Sales, by Application K Units (2018-2023)
  • Table 121. MEA Ioversol Sales, by Country K Units (2018-2023)
  • Table 122. MEA Ioversol Sales, by Type K Units (2018-2023)
  • Table 123. MEA Ioversol Sales, by Application K Units (2018-2023)
  • Table 124. Middle East Ioversol Sales, by Type K Units (2018-2023)
  • Table 125. Middle East Ioversol Sales, by Application K Units (2018-2023)
  • Table 126. Africa Ioversol Sales, by Type K Units (2018-2023)
  • Table 127. Africa Ioversol Sales, by Application K Units (2018-2023)
  • Table 128. North America Ioversol Sales, by Country K Units (2018-2023)
  • Table 129. North America Ioversol Sales, by Type K Units (2018-2023)
  • Table 130. North America Ioversol Sales, by Application K Units (2018-2023)
  • Table 131. United States Ioversol Sales, by Type K Units (2018-2023)
  • Table 132. United States Ioversol Sales, by Application K Units (2018-2023)
  • Table 133. Canada Ioversol Sales, by Type K Units (2018-2023)
  • Table 134. Canada Ioversol Sales, by Application K Units (2018-2023)
  • Table 135. Mexico Ioversol Sales, by Type K Units (2018-2023)
  • Table 136. Mexico Ioversol Sales, by Application K Units (2018-2023)
  • Table 137. Ioversol: by Type(USD/Units)
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Ioversol: by Type(USD Million)
  • Table 144. Ioversol Ioversol 34% Injectable Solution (Optiray 160) , by Region USD Million (2025-2030)
  • Table 145. Ioversol Ioversol 51% Injectable Solution (Optiray 240) , by Region USD Million (2025-2030)
  • Table 146. Ioversol Ioversol 64% Injectable Solution (Optiray 300) , by Region USD Million (2025-2030)
  • Table 147. Ioversol Ioversol 68% Injectable Solution (Optiray 320) , by Region USD Million (2025-2030)
  • Table 148. Ioversol Ioversol 74% Injectable Solution (Optiray 350) , by Region USD Million (2025-2030)
  • Table 149. Ioversol: by Application(USD Million)
  • Table 150. Ioversol X-Ray , by Region USD Million (2025-2030)
  • Table 151. Ioversol CT Scan , by Region USD Million (2025-2030)
  • Table 152. Ioversol Brain Disorders , by Region USD Million (2025-2030)
  • Table 153. Ioversol Blood Vessel Disorders , by Region USD Million (2025-2030)
  • Table 154. Ioversol Heart Disorders , by Region USD Million (2025-2030)
  • Table 155. Ioversol Others , by Region USD Million (2025-2030)
  • Table 156. South America Ioversol, by Country USD Million (2025-2030)
  • Table 157. South America Ioversol, by Type USD Million (2025-2030)
  • Table 158. South America Ioversol, by Application USD Million (2025-2030)
  • Table 159. Brazil Ioversol, by Type USD Million (2025-2030)
  • Table 160. Brazil Ioversol, by Application USD Million (2025-2030)
  • Table 161. Argentina Ioversol, by Type USD Million (2025-2030)
  • Table 162. Argentina Ioversol, by Application USD Million (2025-2030)
  • Table 163. Rest of South America Ioversol, by Type USD Million (2025-2030)
  • Table 164. Rest of South America Ioversol, by Application USD Million (2025-2030)
  • Table 165. Asia Pacific Ioversol, by Country USD Million (2025-2030)
  • Table 166. Asia Pacific Ioversol, by Type USD Million (2025-2030)
  • Table 167. Asia Pacific Ioversol, by Application USD Million (2025-2030)
  • Table 168. China Ioversol, by Type USD Million (2025-2030)
  • Table 169. China Ioversol, by Application USD Million (2025-2030)
  • Table 170. Japan Ioversol, by Type USD Million (2025-2030)
  • Table 171. Japan Ioversol, by Application USD Million (2025-2030)
  • Table 172. India Ioversol, by Type USD Million (2025-2030)
  • Table 173. India Ioversol, by Application USD Million (2025-2030)
  • Table 174. South Korea Ioversol, by Type USD Million (2025-2030)
  • Table 175. South Korea Ioversol, by Application USD Million (2025-2030)
  • Table 176. Australia Ioversol, by Type USD Million (2025-2030)
  • Table 177. Australia Ioversol, by Application USD Million (2025-2030)
  • Table 178. Rest of Asia-Pacific Ioversol, by Type USD Million (2025-2030)
  • Table 179. Rest of Asia-Pacific Ioversol, by Application USD Million (2025-2030)
  • Table 180. Europe Ioversol, by Country USD Million (2025-2030)
  • Table 181. Europe Ioversol, by Type USD Million (2025-2030)
  • Table 182. Europe Ioversol, by Application USD Million (2025-2030)
  • Table 183. Germany Ioversol, by Type USD Million (2025-2030)
  • Table 184. Germany Ioversol, by Application USD Million (2025-2030)
  • Table 185. France Ioversol, by Type USD Million (2025-2030)
  • Table 186. France Ioversol, by Application USD Million (2025-2030)
  • Table 187. Italy Ioversol, by Type USD Million (2025-2030)
  • Table 188. Italy Ioversol, by Application USD Million (2025-2030)
  • Table 189. United Kingdom Ioversol, by Type USD Million (2025-2030)
  • Table 190. United Kingdom Ioversol, by Application USD Million (2025-2030)
  • Table 191. Netherlands Ioversol, by Type USD Million (2025-2030)
  • Table 192. Netherlands Ioversol, by Application USD Million (2025-2030)
  • Table 193. Rest of Europe Ioversol, by Type USD Million (2025-2030)
  • Table 194. Rest of Europe Ioversol, by Application USD Million (2025-2030)
  • Table 195. MEA Ioversol, by Country USD Million (2025-2030)
  • Table 196. MEA Ioversol, by Type USD Million (2025-2030)
  • Table 197. MEA Ioversol, by Application USD Million (2025-2030)
  • Table 198. Middle East Ioversol, by Type USD Million (2025-2030)
  • Table 199. Middle East Ioversol, by Application USD Million (2025-2030)
  • Table 200. Africa Ioversol, by Type USD Million (2025-2030)
  • Table 201. Africa Ioversol, by Application USD Million (2025-2030)
  • Table 202. North America Ioversol, by Country USD Million (2025-2030)
  • Table 203. North America Ioversol, by Type USD Million (2025-2030)
  • Table 204. North America Ioversol, by Application USD Million (2025-2030)
  • Table 205. United States Ioversol, by Type USD Million (2025-2030)
  • Table 206. United States Ioversol, by Application USD Million (2025-2030)
  • Table 207. Canada Ioversol, by Type USD Million (2025-2030)
  • Table 208. Canada Ioversol, by Application USD Million (2025-2030)
  • Table 209. Mexico Ioversol, by Type USD Million (2025-2030)
  • Table 210. Mexico Ioversol, by Application USD Million (2025-2030)
  • Table 211. Ioversol Sales: by Type(K Units)
  • Table 212. Ioversol Sales Ioversol 34% Injectable Solution (Optiray 160) , by Region K Units (2025-2030)
  • Table 213. Ioversol Sales Ioversol 51% Injectable Solution (Optiray 240) , by Region K Units (2025-2030)
  • Table 214. Ioversol Sales Ioversol 64% Injectable Solution (Optiray 300) , by Region K Units (2025-2030)
  • Table 215. Ioversol Sales Ioversol 68% Injectable Solution (Optiray 320) , by Region K Units (2025-2030)
  • Table 216. Ioversol Sales Ioversol 74% Injectable Solution (Optiray 350) , by Region K Units (2025-2030)
  • Table 217. Ioversol Sales: by Application(K Units)
  • Table 218. Ioversol Sales X-Ray , by Region K Units (2025-2030)
  • Table 219. Ioversol Sales CT Scan , by Region K Units (2025-2030)
  • Table 220. Ioversol Sales Brain Disorders , by Region K Units (2025-2030)
  • Table 221. Ioversol Sales Blood Vessel Disorders , by Region K Units (2025-2030)
  • Table 222. Ioversol Sales Heart Disorders , by Region K Units (2025-2030)
  • Table 223. Ioversol Sales Others , by Region K Units (2025-2030)
  • Table 224. South America Ioversol Sales, by Country K Units (2025-2030)
  • Table 225. South America Ioversol Sales, by Type K Units (2025-2030)
  • Table 226. South America Ioversol Sales, by Application K Units (2025-2030)
  • Table 227. Brazil Ioversol Sales, by Type K Units (2025-2030)
  • Table 228. Brazil Ioversol Sales, by Application K Units (2025-2030)
  • Table 229. Argentina Ioversol Sales, by Type K Units (2025-2030)
  • Table 230. Argentina Ioversol Sales, by Application K Units (2025-2030)
  • Table 231. Rest of South America Ioversol Sales, by Type K Units (2025-2030)
  • Table 232. Rest of South America Ioversol Sales, by Application K Units (2025-2030)
  • Table 233. Asia Pacific Ioversol Sales, by Country K Units (2025-2030)
  • Table 234. Asia Pacific Ioversol Sales, by Type K Units (2025-2030)
  • Table 235. Asia Pacific Ioversol Sales, by Application K Units (2025-2030)
  • Table 236. China Ioversol Sales, by Type K Units (2025-2030)
  • Table 237. China Ioversol Sales, by Application K Units (2025-2030)
  • Table 238. Japan Ioversol Sales, by Type K Units (2025-2030)
  • Table 239. Japan Ioversol Sales, by Application K Units (2025-2030)
  • Table 240. India Ioversol Sales, by Type K Units (2025-2030)
  • Table 241. India Ioversol Sales, by Application K Units (2025-2030)
  • Table 242. South Korea Ioversol Sales, by Type K Units (2025-2030)
  • Table 243. South Korea Ioversol Sales, by Application K Units (2025-2030)
  • Table 244. Australia Ioversol Sales, by Type K Units (2025-2030)
  • Table 245. Australia Ioversol Sales, by Application K Units (2025-2030)
  • Table 246. Rest of Asia-Pacific Ioversol Sales, by Type K Units (2025-2030)
  • Table 247. Rest of Asia-Pacific Ioversol Sales, by Application K Units (2025-2030)
  • Table 248. Europe Ioversol Sales, by Country K Units (2025-2030)
  • Table 249. Europe Ioversol Sales, by Type K Units (2025-2030)
  • Table 250. Europe Ioversol Sales, by Application K Units (2025-2030)
  • Table 251. Germany Ioversol Sales, by Type K Units (2025-2030)
  • Table 252. Germany Ioversol Sales, by Application K Units (2025-2030)
  • Table 253. France Ioversol Sales, by Type K Units (2025-2030)
  • Table 254. France Ioversol Sales, by Application K Units (2025-2030)
  • Table 255. Italy Ioversol Sales, by Type K Units (2025-2030)
  • Table 256. Italy Ioversol Sales, by Application K Units (2025-2030)
  • Table 257. United Kingdom Ioversol Sales, by Type K Units (2025-2030)
  • Table 258. United Kingdom Ioversol Sales, by Application K Units (2025-2030)
  • Table 259. Netherlands Ioversol Sales, by Type K Units (2025-2030)
  • Table 260. Netherlands Ioversol Sales, by Application K Units (2025-2030)
  • Table 261. Rest of Europe Ioversol Sales, by Type K Units (2025-2030)
  • Table 262. Rest of Europe Ioversol Sales, by Application K Units (2025-2030)
  • Table 263. MEA Ioversol Sales, by Country K Units (2025-2030)
  • Table 264. MEA Ioversol Sales, by Type K Units (2025-2030)
  • Table 265. MEA Ioversol Sales, by Application K Units (2025-2030)
  • Table 266. Middle East Ioversol Sales, by Type K Units (2025-2030)
  • Table 267. Middle East Ioversol Sales, by Application K Units (2025-2030)
  • Table 268. Africa Ioversol Sales, by Type K Units (2025-2030)
  • Table 269. Africa Ioversol Sales, by Application K Units (2025-2030)
  • Table 270. North America Ioversol Sales, by Country K Units (2025-2030)
  • Table 271. North America Ioversol Sales, by Type K Units (2025-2030)
  • Table 272. North America Ioversol Sales, by Application K Units (2025-2030)
  • Table 273. United States Ioversol Sales, by Type K Units (2025-2030)
  • Table 274. United States Ioversol Sales, by Application K Units (2025-2030)
  • Table 275. Canada Ioversol Sales, by Type K Units (2025-2030)
  • Table 276. Canada Ioversol Sales, by Application K Units (2025-2030)
  • Table 277. Mexico Ioversol Sales, by Type K Units (2025-2030)
  • Table 278. Mexico Ioversol Sales, by Application K Units (2025-2030)
  • Table 279. Ioversol: by Type(USD/Units)
  • Table 280. Research Programs/Design for This Report
  • Table 281. Key Data Information from Secondary Sources
  • Table 282. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Europe Ioversol: by Type USD Million (2018-2023)
  • Figure 5. Europe Ioversol: by Application USD Million (2018-2023)
  • Figure 6. South America Ioversol Share (%), by Country
  • Figure 7. Asia Pacific Ioversol Share (%), by Country
  • Figure 8. Europe Ioversol Share (%), by Country
  • Figure 9. MEA Ioversol Share (%), by Country
  • Figure 10. North America Ioversol Share (%), by Country
  • Figure 11. Europe Ioversol: by Type K Units (2018-2023)
  • Figure 12. Europe Ioversol: by Application K Units (2018-2023)
  • Figure 13. South America Ioversol Share (%), by Country
  • Figure 14. Asia Pacific Ioversol Share (%), by Country
  • Figure 15. Europe Ioversol Share (%), by Country
  • Figure 16. MEA Ioversol Share (%), by Country
  • Figure 17. North America Ioversol Share (%), by Country
  • Figure 18. Europe Ioversol: by Type USD/Units (2018-2023)
  • Figure 19. Europe Ioversol share by Players 2023 (%)
  • Figure 20. BCG Matrix for key Companies
  • Figure 21. Liebel-Flarsheim Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Liebel-Flarsheim Company (United States) Revenue: by Geography 2023
  • Figure 23. Guerbet (France) Revenue, Net Income and Gross profit
  • Figure 24. Guerbet (France) Revenue: by Geography 2023
  • Figure 25. Jiangsu Hengrui Medicine (China) Revenue, Net Income and Gross profit
  • Figure 26. Jiangsu Hengrui Medicine (China) Revenue: by Geography 2023
  • Figure 27. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue: by Geography 2023
  • Figure 29. China Resources Pharmaceutical (Shanghai) Co, (China) Revenue, Net Income and Gross profit
  • Figure 30. China Resources Pharmaceutical (Shanghai) Co, (China) Revenue: by Geography 2023
  • Figure 31. Europe Ioversol: by Type USD Million (2025-2030)
  • Figure 32. Europe Ioversol: by Application USD Million (2025-2030)
  • Figure 33. South America Ioversol Share (%), by Country
  • Figure 34. Asia Pacific Ioversol Share (%), by Country
  • Figure 35. Europe Ioversol Share (%), by Country
  • Figure 36. MEA Ioversol Share (%), by Country
  • Figure 37. North America Ioversol Share (%), by Country
  • Figure 38. Europe Ioversol: by Type K Units (2025-2030)
  • Figure 39. Europe Ioversol: by Application K Units (2025-2030)
  • Figure 40. South America Ioversol Share (%), by Country
  • Figure 41. Asia Pacific Ioversol Share (%), by Country
  • Figure 42. Europe Ioversol Share (%), by Country
  • Figure 43. MEA Ioversol Share (%), by Country
  • Figure 44. North America Ioversol Share (%), by Country
  • Figure 45. Europe Ioversol: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Liebel-Flarsheim Company (United States)
  • Guerbet (France)
  • Jiangsu Hengrui Medicine (China)
  • Mallinckrodt Pharmaceuticals (United Kingdom)
  • China Resources Pharmaceutical (Shanghai) Co, (China)
Additional players considered in the study are as follows:
Novalek Pharmaceuticals Pvt. Ltd (India) , Stellence Pharmscience Pvt. Ltd (India) , A.S. Joshi & Company (India)
Select User Access Type

Key Highlights of Report


Mar 2024 170 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ioversol Quantitative research analysis
Global Ioversol Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2030
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Precautions Required Before Ioversol Injection
  • Stringent Regulatory Frameworks Related to Ioversol Chemical

Know More About Global Ioversol Report?

Have a Query? Click Here

Other Related Reports

Sodium Lauroyl Isethionate Comprehensive Study by Type (Chips/Flakes, Powders, Granules), Application (Hair Care, Skin Care, Others) Players and Region - Global Market Outlook to 2027
$ 3400
High-performance Anti-corrosion Coatings Comprehensive Study by Type (Epoxy, Urethane, Acrylic, Others), Application (Oil & Gas, Marine, Construction, Tanks & Pipes, Power Generation, Others), Techno...
$ 3450
Lapping Film Comprehensive Study by Type (Metalized Film, Shrink Film, Stretch Film, Adhesive Film), Application (Food and Medicine Film, Photovoltaic Film, Packaging Film, Shipping Labels, Cling Fil...
$ 3450
High Performance Epoxy Comprehensive Study by Type (Epoxy, Polyurethane, Acrylic, Silicone, Others), Application (Warehouse and garage floors, Manufacturing plants, Education facilities, Pharmaceutic...
$ 3650
Vanadium Comprehensive Study by Application (Steel Alloys, Ceramics, Dyes, Others), Vanadium Minerals (Patronite, Carnotite, Vanadinite, Others), Form (Lumps, Powder, Waffle, Ingot, Others) Players a...
$ 3500
Engineering Resins Comprehensive Study by Type (Polyethylene (LDPE,MDPE,HDPE,LLDPE,UHMWPE), Polyvinyl Chloride (PVC), Polybutylene Terephthalate (PBT), Acrylonitrile Butadiene Styrene (ABS), Nylon (N...
$ 3750